Jeff Hackman, CEO of Comera Life Sciences, discusses how the company uses its proprietary SQore™ viscosity reduction platform to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. High viscosity is a significant hurdle to formulating subcutaneous biologics and Comera’s addition of excipients, such as caffeine, interrupts intermolecular interactions to reduce viscosity of high concentration monoclonal antibody formulations. These self-administered SQ biologics have significant potential benefits over IV infusion for patients and payers. Comera is leveraging its SQore platform in multiple ongoing collaborations with biopharma companies to enhance both commercial biologics and those in early development stages. For more information on Comera Life Sciences, visit https://comeralifesciences.com.

#biologics #formulation #drugdelivery

Jeffrey S. Hackman is Chairman and Chief Executive Officer of Comera Life Sciences. Prior to joining Comera, Jeff was President of US Operations for EUSA, a global pharmaceutical company focused on oncology and rare diseases. Previously, he had been acting CEO of Novelion Therapeutics, where he transformed the company to profitability. He joined Novelion from Shire Inc., where he had been Senior VP and Head of US Internal Medicine / Oncology Franchise. Previously, he established the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He has also held senior roles in several other pharmaceutical companies.